Health CareMedical Equipment and Services
  • Price (DKK)71.84
  • Today's Change1.40 / 1.99%
  • Shares traded838.05k
  • 1 Year change-69.75%
  • Beta1.2625
Data delayed at least 15 minutes, as of Aug 08 2022 12:34 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.

  • Revenue in DKK (TTM)4.15bn
  • Net income in DKK256.00m
  • Incorporated1956
  • Employees4.91k
  • Location
    Ambu A/SBaltorpbakken 13BALLERUP 2750DenmarkDNK
  • Phone+45 72252000
  • Fax+45 72252050
  • Websitehttps://www.ambu.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Medistim ASA328.88m69.24m3.84bn116.0055.1715.6044.2511.675.085.0824.1517.981.110.92646.913,799,785.0023.4222.1628.3427.7977.7777.2121.0518.822.9179.100.227474.6417.669.7731.0018.38--16.47
Xvivo Perfusion AB234.87m16.74m4.67bn115.00280.004.84100.3719.890.78750.787511.1445.530.23971.274.173,562,402.001.71-0.30341.81-0.325871.3373.367.13-1.185.51--0.0048--43.6613.34118.6440.2735.61--
CellaVision AB460.19m101.41m6.00bn225.0059.1614.2847.3013.045.935.9326.9224.590.81821.827.343,210,715.0018.0318.7221.3622.7269.4570.7022.0421.741.9121.770.169829.0419.9616.3740.0715.9529.895.92
Synsam AB (publ)-71.66bn-71.66bn6.66bn2.98k--3.54----------17.52------------------------0.6959--0.5497--22.67--126.15------
Biotage AB1.02bn162.68m9.47bn499.0058.168.9242.079.253.443.4421.6622.440.80052.296.282,873,240.0012.7314.8715.4817.8061.3461.3715.9017.181.6515.960.115844.4712.7913.0316.9217.183.334.40
Arjo AB (publ)6.79bn464.39m9.83bn6.59k22.681.998.321.452.382.3834.7927.110.62243.506.391,445,987.
Revenio Group Oyj653.28m151.24m10.35bn188.0068.5917.4457.5815.840.75960.75963.282.990.76567.378.82477,054.3017.6416.3120.6919.9850.0551.8823.0422.281.61--0.226969.8429.0027.4429.6324.259.80-14.40
Ossur hf5.23bn415.92m12.94bn3.67k31.272.8715.992.470.97840.978412.3910.650.57922.546.681,426,482.004.735.595.706.5062.3263.038.178.700.79411.550.411610.0714.166.65929.844.631.66--
Ambu A/S4.15bn256.00m15.74bn4.91k70.014.3031.473.791.011.0116.3216.380.69932.046.35905,759.204.317.125.029.0460.1960.096.179.391.07--0.268730.1512.5014.002.49-0.241232.50-1.32
Elekta AB (publ)10.43bn827.72m19.25bn4.75k24.113.1212.241.853.023.0238.0723.330.56883.782.773,061,882.004.524.848.368.8637.3741.037.948.880.8948--0.389855.055.706.33-7.9755.9812.7119.14
GN Store Nord A/S15.52bn1.09bn35.56bn7.75k30.945.5014.762.298.388.38120.0447.090.69253.255.372,147,759.
Getinge AB19.45bn1.91bn40.16bn10.99k22.532.1612.502.069.799.7999.67102.140.60232.586.562,530,152.005.983.347.264.4548.9048.069.925.781.4028.170.160140.67-9.294.06-8.3133.59-10.3615.20
Demant A/S18.39bn2.51bn63.77bn18.12k25.848.33--3.4710.7110.7178.3133.220.7862.115.871,015,014.0010.818.8917.8014.4875.1375.2313.7511.630.503123.540.58690.0027.298.94124.1711.4911.83--
Data as of Aug 08 2022. Currency figures normalised to Ambu A/S's reporting currency: Danish Krone DKK

Institutional shareholders

28.29%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Jun 202219.35m8.66%
Allianz Global Investors GmbHas of 30 Jun 202211.55m5.17%
Capital Research & Management Co. (World Investors)as of 30 Jun 20229.52m4.26%
The Vanguard Group, Inc.as of 08 Jul 20224.40m1.97%
Norges Bank Investment Managementas of 31 Dec 20214.07m1.82%
Brown Capital Management LLCas of 31 Mar 20223.94m1.77%
Bellevue Asset Management AGas of 30 Jun 20223.32m1.49%
Groupama Asset Management SAas of 31 Dec 20212.41m1.08%
Union Investment Privatfonds GmbHas of 31 Mar 20222.38m1.07%
Zadig Asset Management LLPas of 30 Apr 20222.26m1.01%
More ▼
Data from 31 Dec 2021 - 31 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.